AVN944 is a biotech drug that demonstrated a statistically meaningful impact on IMPDH and other proteins that are critical to activities in cancer cells, including nucleotide biosynthesis, energy and metabolism,... AVN944 has been associated with cancer cell death in clinical trials.
- Mechanism
- Curator reviewed
AVN944 inhibits IMPDH and appears to induce apoptosis. Specifically, it was found that the gene HspA1A, a marker of stress response found to correlate with depleted GTP pools in cancer cell lines, is induced within hours upon the first treatment of the drug in patients, even at the trial's lowest doses. Following continued dosing of AVN944, this marker of disease cell stress was elevated even in the absence of circulating levels of the drug between doses.
- Primary indication
- Investigated for use/treatment in cancer/tumors (unspecified), leukemia (unspecified), lymphoma (unspecified), multiple myeloma, and pancreatic cancer.Curator reviewed
- Code names
- AVN-944
Resolves to
What you can answer from here — as of June 15, 2026
Which companies are running trials of AVN-944, in which indications and phases, and which of those programs are still active?
Create a free account or log in to explore the full data card.
Create Account